Fetal precursor cell transplantation has been recognized for years by public, media, and European physicians, as therapeutically very valuable, particularly for those diseases with currently no known therapy, or where the ‘state-of-art’ treatment lost effectiveness, i.e. for incurable and no longer treatable diseases. It took a century since the first patients were so treated in western Europe, or 83 years since its official declaration in Switzerland as a new item in physician’s therapeutic armamentarium.
Medical publications by newcomers to this field fail to acknowledge that during the past 83 years an ample research has been undertaken, enormous clinical experience gained by fetal precursor cell transplantation treatment of over 5 million patients in Germany alone. Plentiful of papers have been published in ‘peer-reviewed journals’ of countries where this treatment originated. Medical progress has always been based on the past discoveries, all the while the structure and function of human body have not changed for thousands of years. Contrary to this principle, all that has been learned about fetal precursor cell transplantation, and reported in medical journals and meetings over the past 100 years, is ignored today like in the Middle Ages when due to the same attitude the progress of medicine was set back for centuries.
Embryonic stem cell transplantation is spoken about incessantly in the recent U.S. medical literature, even though there is no ‘Mother-of-All-Cells’, or ‘Universal Cell’, from which allegedly are made any & all of ~ 220 types of cells making up the body of any member of animal kingdom, including ‘Homo Sapiens’. Human or animal bodies are created by union of sperm and ovum, not from a cell line of one embryonic stem cell propagated in the laboratory dish. Only cancerous growth is created that way.
Umbilical cord blood of human newborn contains hematopoietic and mesenchymal stem cells only, but not ‘Universal Cells’.
You may get confused when terms ‘stem cell transplantation , ‘cell transplantation’, ‘fetal precursor cell transplantation’, are used side by side in publications. The term ‘stem cell transplantation’ has been favored by a group of newcomers to this field versed in laboratory techniques but not in clinical practice of fetal precursor cell transplantation. Experienced practitioners of fetal precursor cell transplantation recognized decades ago that cell transplants of various organs or tissues contain all generations of the family of a certain cell type, including those of the fetal precursor cells.
Method of fetal precursor cell transplantation described in this text is not a ‘magic bullet’, i.e. a treatment of all known diseases. It is of minimal usefulness in the therapy of some diseases, e.g. chronic inflammatory diseases, many psychiatric diseases, etc.
At the same time, all patients with diseases with no known treatment, e.g. genetic or chromosomal diseases, perinatal brain injuries, classical autism (Kanner, 1943), should be treated with fetal precursor cell transplantation or therapy immediately after the diagnosis was made as time is of essence. Fetal precursor cell transplants prepared by a method described in this text are safer than aspirin, and our experience has proven that there is no harm by trying to treat newborn and infants born with rare inborn diseases, and not be preoccupied by a lack of medical reports about that particular very rare illness or disease.
There is no competition between an adequate ‘standard’ treatment of a disease and fetal precursor cell therapy. For example, type 1 diabetics must be treated by insulin alone until they develop complications; at that time fetal precursor cell transplantation has to be added, since insulin alone cannot control the progression of diabetic retinopathy, diabetic nephropathy, peripheral arterial disease, etc., toward blindness, kidney failure, gangrene, impotence, etc.
Sometimes the cost has to be considered. Gaucher’s disease is an inborn enzymopathy, where the missing enzyme was identified, purified, and is commercially available, but at an astronomical price that is hardly affordable by any patient. Fetal precursor cell transplantation can offer the same therapeutic benefit for the fraction of the commercial cost of the enzyme.
As the diagnosis is frequently nothing but a label used for insurance billing, covering the mandatory use of drugs for treatment nowadays, even if not effective, the patient selection for fetal precursor cell transplantation treatment has to be based on the analysis of the pathophysiology of the illness(es) that a patient suffers from the cytological angle that has never been taught in medical schools. A physician has to process in his mind the clinical findings from a different angle in order to establish a pathophysiological diagnosis(es) of the patient. The selection of fetal precursor cell transplants to be used for treatment is based on such pathophysiological diagnosis. It may take time to re-train your brain, conditioned for years or decades to use established diagnostic labels, toward analysis of the pathophysiology of the patient’s medical condition(s) on a cytological level.
In the clinical part of this text the author has focused on diseases where there is a substantial clinical experience with fetal precursor cell transplantation, and a success well above the 50% considered satisfactory today by regulatory agencies for a new drug approval. Such clinical knowledge can be extrapolated onto other diseases with a similar pathogenesis. As an example, if a certain single gene disorder has been successfully treated by fetal precursor cell transplantation, it means that all other genetic diseases due to a single gene disorder can be treated by fetal precursor cell therapy with success. One has to find out only in which type of cell is the gene defect located, and the pathophysiological diagnosis has to be made soon after birth, so that the fetal precursor cell transplantation treatment can get started already 4 to 8 weeks after birth, and be repeated every 3 – 4 months up prior to the age of 4 years.
The purpose of this text is to present the field of fetal cell transplantation as it has evolved during the past 100 years, and as it is practiced today by physicians that have acquired knowledge of the preceding generations of physicians by studying the publications and taking ‘hands-on’ clinical training.
How to use this textbook?
If you are new to the fetal precursor cell transplantation, you should read this text from cover to cover at' least three times. It contains all that you have to know for a clinical practice of this new medical field. The author has done it all during the past 38 years: study of the past known medical facts, research, development of the method of preparation of BCRO fetal precursor cell transplants individually for each patient, from human as well as animal fetuses, clinical practice of fetal cell allo- and xeno-transplantation, detailed analysis of the past as well as own clinical data. All this knowledge and experience is expressed' in this text.
For those physicians that have already treated their patients by BCRO fetal precursor cell transplantation this text can serve as a guide to the types of diseases that have been successfully handled by this treatment modality, and learning at what stage of disease has this treatment been most efficient.
Finally, this text explains why fetal precursor cell 'xeno'-transplantation is much more versatile and therapeutically effective than cell 'allo'-transplantation, including bone marrow transplantation or umbilical cord blood cell transplantation, and superior in its safety.
Human adult cell transplantation cannot compete in its clinical results with fetal precursor cell transplantation. BCRO fetal precursor cell transplantation is the answer for a great majority of therapeutic problems when everything else known to medicine has failed.